Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3
of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell
lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international
prognostic index (Aa-IPI).